Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Dose-escalation, Blinded Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children (9 to <18 Years of Age)

NCT07870330 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT07870330
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07870330 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Dose-escalation, Blinded Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children (9 to <18 Years of Age)
Lead sponsor
ModernaTX, Inc.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 7, 2026
Completion date
December 7, 2027
Enrollment
96 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

seasonal influenza